首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation.
【24h】

Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation.

机译:额外的单克隆抗体(mAB)注射可以代替胸腺照射,从而在接受抗T细胞mAB和3-Gy全身照射调节后,在接受骨髓移植的小鼠中诱导混合嵌合体和耐受性。

获取原文
获取原文并翻译 | 示例
           

摘要

While allogeneic bone marrow transplantation (BMT) has long been known to be capable of inducing donor-specific tolerance and hence permitting allograft acceptance without immunosuppressive pharmacotherapy, the toxicity of conditioning regimens required to achieve marrow engraftment has precluded the application of this approach to clinical organ transplantation. A relatively nontoxic method of conditioning mice that allows allogeneic bone marrow engraftment and induction of donor-specific skin allograft tolerance has recently been described. This regimen included anti-CD4 and anti-CD8 mAbs administered on day -5, followed by 3-Gy whole body irradiation (WBI) and 7-Gy thymic irradiation (TI) on day 0. To further reduce the potential toxicity of this regimen, we have now attempted to overcome the requirement for TI by administering additional mAb injections before and after BMT. Mixed chimerism and prolonged donor-specific skin graft acceptance were induced in 90% of B10 mice conditioned with anti-CD4 and -CD8 mAbs on days -6 and -1 and 3-Gy WBI on day 0 without TI. Despite long-term acceptance of donor-specific skin grafts, however, some of these animals showed a gradual decline in donor-type hematopoietic repopulation, and 2 of 10 mice regrafted with a second donor-type skin graft 5-9 months after BMT rejected the second and/or the original graft. This rejection after repeat donor-specific skin grafting correlated with a decline in the percentage of donor-type T cells between 6 and 12 weeks after BMT. In contrast, all animals receiving additional mAb injections 7 and 14 days following BMT after conditioning with mAbs on days -6 and -1 and 3-Gy WBI showed stable chimerism and accepted both primary and secondary donor-specific skin grafts. Animals receiving TI in addition to mAb and 3-Gy WBI also showed stable chimerism and long-term acceptance of initial (at 7 weeks) and later repeat donor-specific grafts. In contrast, the majority of mice receiving mAbs only on day -5 or on day -1 only, followed by 3-Gy WBI on day 0 without TI, did not accept initial donor-specific skin grafts, and showed only transient chimerism. Thus, the requirement for thymic irradiation to allow permanent mixed chimerism and donor-specific tolerance induction can be overcome by the administration of additional T cell-depleting mAb injections. These results establish a less toxic method of inducing donor-specific tolerance, thus increasing the potential clinical applicability of this approach to inducing organ allograft acceptance without chronic immunosuppressive therapy.
机译:尽管长期以来,异基因骨髓移植(BMT)能够诱导供体特异性耐受,因此无需免疫抑制药物治疗即可接受同种异体移植,但实现骨髓移植所需的条件疗法的毒性却使得该方法无法应用于临床器官移植。最近已经描述了一种调节小鼠的相对无毒的方法,其允许同种异体骨髓移植并诱导供体特异性皮肤同种异体移植耐受性。该方案包括在第-5天施用抗CD4和抗CD8 mAb,然后在第0天进行3-Gy全身辐射(WBI)和7-Gy胸腺辐射(TI)。为进一步降低该方案的潜在毒性,我们现在已经尝试通过在BMT之前和之后再注射mAb来克服TI的要求。 90%的B10小鼠在-6天,-1天和-1天以及3-Gy WBI在0天没有TI的条件下诱导了混合嵌合体和延长的供体特异性皮肤移植接受性。尽管长期接受了供体特异性皮肤移植,但是其中一些动物显示供体型造血的种群逐渐减少,在BMT拒绝5-9个月后的10只小鼠中,有2只接受了第二次供体型皮肤移植第二和/或原始移植物。重复供体特异性皮肤移植后的排斥反应与BMT后6至12周间供体型T细胞百分比的下降有关。相比之下,在第-6天,第-1天和第3天Gy WBI进行mAb适应后,BMT后第7天和第14天接受额外mAb注射的所有动物均表现出稳定的嵌合状态,并接受了初次和二次供体特异性皮肤移植。除了mAb和3-Gy WBI以外,接受TI的动物也表现出稳定的嵌合性,并在最初(第7周)和以后重复供体特异性移植物方面得到了长期接受。相反,大多数小鼠仅在第-5天或仅在第-1天接受mAb,然后在第0天没有TI的情况下接受3-Gy WBI,不接受最初的供体特异性皮肤移植,仅表现出短暂的嵌合现象。因此,可以通过给予其他消耗T细胞的mAb注射来克服胸腺照射以实现永久混合嵌合和诱导供体特异性耐受的要求。这些结果建立了一种诱导供体特异性耐受的毒性较小的方法,从而提高了这种方法在不进行慢性免疫抑制治疗的情况下诱导器官同种异体移植接受的潜在临床适用性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号